For The Steroids For Corneal Ulcers Trial Group

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
plete in its description regarding how the study was conducted and how the numerous statistical challenges were handled. The conclusions the authors made regarding a significantly lower hazard ratio for death when using ranibizumab compared with PDT or pegaptanib and a similar significant reduction in the hazard ratio for MI when comparing ranibizumab with(More)
  • 1